Antisense Therapeutics (ASX: ANP)

Last close As at 28/03/2024

0.07

0.00 (−2.94%)

Market capitalisation

60m

Antisense Therapeutics is an Australian biotechnology company developing antisense oligonucleotide (ASO) therapies for the treatment of rare diseases. Its lead asset, ATL1102, is being investigated as a targeted anti-inflammatory therapy to treat Duchenne muscular dystrophy (DMD). In a positive strategic pivot, trial design was amended to a smaller Phase IIb study (n=42 vs 108) that should provide a nearer-term catalyst, if positive readouts are achieved. As a result of the reduced trial costs, the company’s cash runway is anticipated to be extended (net cash at end-June 2022 of A$19.2m) into Q4 CY23. Management envisages a need to raise funds in the mid-single digit (A$m) region, which it anticipates will fund operations to trial readouts in Q124.

Edison Investment Research is terminating coverage on Antisense Therapeutics (ANP). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 30.8 (10.5) (28.4)
Relative 33.4 (11.6) (30.3)
52 week high/low A$0.1/A$0.0

Further insights

insight

Healthcare

Healthcare Week 2023

Analyst of the week

Andy Murphy

Andy Murphy

Director, Financials & Industrials

Read latest

Thematics

thematic

Investment Companies

Listed private equity – Performing a balancing act

thematic

Consumer

ConsumerWatch – At least someone loves me

thematic

TMT

MediaWatch – Rinse and repeat

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free